In this large trial of patients with acute coronary syndrome undergoing PCI, they were randomized to high or low dose ASA (325mg vs 81mg) and high or low clopidogrel (600mg, followed by 150mg for a week, then 75mg/day, versus 300mg, followed by 75mg/day). The high dose clopidogrel group had lower 30 day CV death/MI/stroke (3.9% vs 4.5%), but ASA dose did not affect the primary outcome. High dose clopidogrel did increase the risk of major bleeding (1.6% vs 1.1%) (abstract)
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment